Aeglea BioTherapeutics
Signal active
Organization
Contact Information
Overview
Aeglea BioTherapeutics is a clinical-stage biotechnology company that develops enzyme therapies for rare metabolic diseases. It competes in the segments of the pharmaceutical, biotechnology, and other related markets that address rare genetic diseases.
About
Industries
Biotechnology, Health Care, Therapeutics
Founded
2013
Employees
101-250
Headquarters locations
Austin, Texas, United States, North America
Social
Profile Resume
Aeglea BioTherapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Therapeutics sector. The company focuses on Biotechnology and has secured $9.6B in funding across 36 round(s). With a team of 101-250 employees, Aeglea BioTherapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Aeglea BioTherapeutics, raised $12.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
4
Lead Investors
0
Total Funding Amount
$266.0M
Details
2
Aeglea BioTherapeutics has raised a total of $266.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2015 | Early Stage Venture | 44.0M | ||
| 2014 | Early Stage Venture | 12.0M |
Investors
Aeglea BioTherapeutics is funded by 21 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Lilly Ventures | - | FUNDING ROUND - Lilly Ventures | 12.0M |
| Novartis Venture Fund | - | FUNDING ROUND - Novartis Venture Fund | 12.0M |
| Aeglea BioTherapeutics | - | FUNDING ROUND - Aeglea BioTherapeutics | 12.0M |
| UT Horizon Fund | - | FUNDING ROUND - UT Horizon Fund | 12.0M |
Recent Activity
News
Apr 29, 2024
Yahoo Movies UK - Having purchased US$1.8m worth of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) stock, the recent 53% pullback is ...
News
Apr 17, 2024
LinkedIn - DealStreetAsia on LinkedIn: Biotech startup Arnatar raises $50m Series A round to build China presence
News
Apr 09, 2024
LinkedIn - DealStreetAsia on LinkedIn: Biotech startup Arnatar raises $50m Series A round to build China presence
News
Nov 28, 2023
PR Newswire - Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and ...
Funding Round
Jun 22, 2023
Aeglea BioTherapeutics raised $210000000 on 2023-06-22 in Post-IPO Equity
News
Apr 11, 2023
Google Patent - Treatment of arginase 1 deficiency